Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease

Bone Marrow Transplantation

Volumn 41, Issue 3, 2008, Pages 293-302

  Wang, Y ^a,b   Ogawa, Y ^a   Dogru, M ^a,c   Kawai, M ^a   Tatematsu, Y ^a   Uchino, M ^a   Okada, N ^a   Igarashi, A ^a   Kujira, A ^a   Fujishima, H ^a   Okamoto, S ^a   Shimazaki, J ^a,c   Tsubota, K ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUDAN UNIVERSITY   (China)

^c TOKYO DENTAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL TEAR; CYCLOSPORIN; CYCLOSPORIN A; EYE DROPS; MUCIN 5AC; PREDNISOLONE; RETINOL;

ADULT; AGED; ARTICLE; CELL COUNT; CELL DENSITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORNEA SENSIBILITY; DRUG EFFICACY; DRUG WITHDRAWAL; DRY EYE; EVENING DOSAGE; EYE IRRITATION; FEMALE; GENE EXPRESSION; GOBLET CELL; HUMAN; INFLAMMATORY CELL; LACRIMATION; MALE; MORNING DOSAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SCHIRMER TEST; SCORING SYSTEM; SQUAMOUS CELL METAPLASIA; VISUAL ANALOG SCALE; VITAL STAIN;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS; CHRONIC DISEASE; CONJUNCTIVA; CORNEA; CYCLOSPORINE; DRY EYE SYNDROMES; FEMALE; GOBLET CELLS; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; MUCINS; OPHTHALMIC SOLUTIONS; PATIENT SATISFACTION; PILOT PROJECTS; TEARS; TREATMENT OUTCOME;

EID: 39349110186     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705900     Document Type: Article

References (36)

1. Horowitz M. Uses and growth of hematopoietic cell transplantation immunology. In: Blume KG, Forman SJ, Applebaum FR (eds). Thomas' Hematopoietic Cell Transplantation, 3rd edn. Blackwell: Malden, MA, 2004, pp 9-15.
2. Martin PJ. Overview of hematopoietic cell transplantation. In: Blume KG, Forman SJ, Applebaum FR (eds). Thomas' Hematopoietic Cell Transplantation, 3rd edn. Blackwell: Malden, MA, 2004, pp 16-30.
3. Ogawa Y, Kuwana M. Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea 2003; 22: S19-S27.
4. Franklin RM, Kenyon KR, Tutschka PJ, Saral R, Green WR, Santos GW. Ocular manifestations of graft-vs-host disease. Ophthalmology 1983; 90: 4-13.
5. Ogawa Y, Okamoto S, Wakui M, Watanabe R, Yamada M, Yoshino M et al Dry eye after hematopoietic stem cell transplantation. Br J Ophthalmol 1999; 83: 1125-1130.
6. Hirst LW, Jabs DA, Tutschka PJ, Green WR, Santos GW. The eye in bone marrow transplantation. I. Clinical study. Arch Ophthalmol 1983; 101: 580-584.
7. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
8. Mencucci R, Rossi Ferrini C, Bosi A, Volpe R, Guidi S, Salvi G. Ophthalmological aspects in allogenic bone marrow transplantation: Sjogren-like syndrome in graft-versus-host disease. Eur J Ophthalmol 1997; 7: 13-18.
9. Tichelli A, Duell T, Weiss M, Socie G, Ljungman P, Cohen A et al. Late-onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: Incidence and risk factors. European group for blood and marrow transplantation (EBMT) Working party on late effects. Bone Marrow Transplant 1996; 17: 1105-1111.
10. Ogawa Y, Okamoto S, Mori T, Yamada M, Mashima Y, Watanabe R et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant 2003; 31: 579-583.
11. Murphy PT, Sivakumaran M, Fahy G. Hutchinson RM. Successful use of topical retinoic acid in severe dry eye due to chronic graft-versus-host disease. Bone Marrow Transplant 1996; 18: 641-642.
12. Rocha EM, Pelegrino FS, de Paiva CS, Vigorito AC, de Souza CA. GVHD dry eyes treated with autologous serum tears. Bone Marrow Transplant 2000; 25: 1101-1103.
13. Ogawa Y, Okamoto S, Kuwana M, Mori T, Watanabe R, Nakajima T et al Successful treatment of dry eye in two patients with chronic graft versus host disease with systemic administration of FK506 and corticosteroids. Cornea 2001; 20: 430-434.
14. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multi-center, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000; 107: 631-639.
15. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: A dose-ranging, randomized trial. The cyclosporin A phase 2 study group. Ophthalmology 2000; 107: 967-974.
16. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safey evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 2005; 112: 1790-1794.
17. Shimazaki J, Goto E, Ono M, Shimmura S, Tsubota K. Meibomian gland dysfunction in patients with Sjogren syndrome. Ophthalmology 1998; 105: 1485-1488.
18. Kojima T, Ishida R, Dogru M, Goto E, Matsumoto Y, Kaido M et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: A prospective randomized case-control study. Am J Ophthalmol 2005; 139: 242-246.
19. Tsubota K, Yamada M. Tear evaporation from the ocular surface. Invest Ophthalmol Vis Sci 1992; 33: 2942-2950.
20. Goto E, Endo K, Suzuki A, Fujikura Y, Matsumoto Y, Tsubota K et al Tear evaporation dynamics m normal subjects and subjects with obstructive meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2003; 44: 533-539.
21. Toda I, Tsubota K. Practical double vital staining for ocular surface evaluation. Cornea 1993; 12: 366-367.
22. Nelson JD. Impression cytology. Cornea 1988; 7: 71-81.
23. Dogru M, Asano-Kato N, Tanaka M, Igarashi A, Shimmura S, Shimazaki J et al. Ocular surface and MUC5AC alterations in atopic patients with corneal shield ulcers. Curr Eye Res 2005; 30: 897-908.
24. Miyoshi T, Fukagawa K, Shimmura S, Fujishima H, Takano Y, Takamura E et al. Interleukin-8 concentrations in conjunctival epithelium brush cytology samples correlate with neutrophil, eosinophil infiltration, and corneal damage. Cornea 2001; 20: 743-747.
25. Pflugfelder SC. Anti-inflammatory therapy of dry eye. Ocul Surf 2003; 1: 31-36.
26. Nishida T. Neurotrophic mediators and corneal wound healing. Ocul Surf 2005; 3: 194-202.
27. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 2002; 120: 330-337.
28. Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology 2007; 114: 76-79.
29. Tatlipinar S, Akpek EK. Topical cyclosporin in the treatment of ocular surface disorders. Br J Ophthalmol 2005; 89: 1363-1367.
30. Rao SN, Rao RD. Efficacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease. Cornea 2006; 25: 674-678.
31. Lelli Jr GJ, Musch DC, Gupta A, Farjo QA, Nairus TM, Mian SI et al Ophthalmic cyclosporine use in ocular GVHD. Cornea 2006; 25 635-638.
32. Ogawa Y, Kuwana M, Yamazaki K, Mashima Y, Yamada M, Mori T et al. Periductal area as the primary site for T-cell activation in lacrimal gland chronic graft-versus-host disease. Invest Ophthalmol Vis Sci 2003; 44: 1888-1896.
33. Ogawa Y, Yamazaki K, Kuwana M, Mashima Y, Nakamura Y, Ishida S et al A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD. Invest Ophthalmol Vis Sci 2001; 42: 111-119.
34. Duncan N, Craddock C. Optimizing the use of cyclosporin in allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 38: 169-174.
35. Tsubota K, Fujita H, Tadano K, Takeuchi T, Murakami T, Saito I et al Improvement of lacrimal function by topical application of CyA in murine models of Sjögren's syndrome. Invest Ophthalmol Vis Sci 2001; 42: 101-110.
36. Tsubota K, Saito I, Ishimaru N, Hayashi Y. Use of topical cyclosporin A in a primary Sjögren's syndrome mouse model. Invest Ophthalmol Vis Sci 1998; 39: 1551-1559.